Bilateral Nonsynchronous Male Breast Cancer: Two Case Reports

Horimoto, Yoshiya; Hino, Mako; Saito, Mitsue; Arakawa, Atsushi; Matsumoto, Takeshi; Kasumi, Fujio

doi:10.1159/000116119

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the USA, at the time of diagnosis, only 12.8 to 15.6% of patients are at stage III and 5.4 to 8.9% at stage IV [ 12 , 21 ]. In Japan, all the eight cases published by Horimoto were at a stage inferior to III [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

Male breast cancer: diagnosis stages, treatment and survival in a country with limited resources (Burkina Faso)

et al. 2018

View full text Add to dashboard Cite

BackgroundMale breast cancer is a rare and less known disease. Therapeutic modalities affect survival. In Burkina Faso, male breast cancers are diagnosed in everyday practice, but the prognosis at short-, middle-, and long-term remains unknown. The objective of this study is to study the diagnosis stages, therapeutic modalities, and 5-year survival in male breast cancer at the General Surgery Unit of Yalgado Ouedraogo University Hospital from 1990 to 2009.MethodsA cohort longitudinal study concerning cases of breast cancer diagnosed in man. Survival was assessed using the Kaplan–Meier method and survival curves were compared through the LogRank test.ResultsFifty-one cases of male breast cancer were followed-up, i.e., 2.6% of all breast cancers. Stages III and IV represented 88% of cases. Eleven patients (21.6%) were at metastatic stage. Patients were operated in 60.8% of cases. The surgery included axillary dissection in 25 (80.6%) out of 31 cases. Lumpectomy was performed on 6.5% of patients (2 cases). Fifteen (29.4%) and 11 (21.6%) patients underwent chemotherapy and hormonal therapy, respectively. The FAC protocol was mostly used. Radiation therapy was possible in two cases. The median deadline for follow-up was 14.8 months. A local recurrence was noticed in 3.2% of cases. The overall 5-year survival rate was 49.9%. The median survival was over 5 years for stages I and II. It was 54 down to 36 months for stages III and IV.ConclusionDiagnosis is late. The lack of immunohistochemistry makes it difficult to define the proportion of their hormonal dependence. Surgery is the basic treatment. Five-year survival is slow and the median survival depends on the diagnosis stage. It can be improved through awareness-raising campaigns and the conduct of individual screening.

show abstract

Section: Discussionmentioning

confidence: 99%

Male breast cancer: diagnosis stages, treatment and survival in a country with limited resources (Burkina Faso)

et al. 2018

View full text Add to dashboard Cite

show abstract

Aromatase inhibitors in male breast cancer: a pooled analysis

Zagouri¹,

Sergentanis²,

Azim

et al. 2015

Breast Cancer Res Treat

View full text Add to dashboard Cite

Although several studies have shown the efficacy of third-generation aromatase inhibitors (AIs) in women with breast cancer, the role of such molecules remains elusive in male breast cancer patients. It is also unknown whether the addition of gonadotropin-releasing hormone (GnRH) analogues to AIs would be a superior strategy or not. This pooled analysis was conducted in accordance with the PRISMA guidelines. All studies that examined the efficacy of AIs in metastatic male breast cancer were considered eligible. Overall, 15 studies (105 cases) were eligible for this pooled analysis. The mean age of the study sample was 62.8 years. ER status was positive in all eligible cases. AI was given as first line in 61.5 % of cases. GnRH analogue was co-administered with AI in 37.1 % of cases (n = 39). CR, PR, SD and PD were achieved in 5.7, 23.8, 37.2 and 33.3 % of cases, respectively. The median PFS and OS were equal to 10.0 and 39.0 months, respectively. Co-administration of GnRH analogues was associated with more than threefold increase in rates of clinical benefit (OR = 3.37, 95 % CI 1.30-8.73) but did not seem to correlate with better PFS or OS. No statistically significant associations between the examined outcomes and the other parameters were noted. Available data suggest that AIs may potentially play a promising role in the optimal therapeutic strategy for metastatic male breast cancer patients. Especially, co-administration of AI with a GnRH analogue seems to increase the rate of clinical benefit and could be more effective, warranting further consideration.

show abstract

Bilateral Nonsynchronous Male Breast Cancer: Two Case Reports

Cited by 2 publications

References 10 publications

Male breast cancer: diagnosis stages, treatment and survival in a country with limited resources (Burkina Faso)

Male breast cancer: diagnosis stages, treatment and survival in a country with limited resources (Burkina Faso)

Aromatase inhibitors in male breast cancer: a pooled analysis

Contact Info

Product

Resources

About